Asset Purchase Deals in Pharmaceuticals and Biotechnology 2019-2026

Description

Benchmark Asset Acquisition Strategies Across the Global Biopharma Industry

Free report sample

The Asset Purchase Deals in Pharmaceuticals and Biotechnology 2019-2026 report provides a comprehensive analysis of asset acquisition transactions across the global life sciences industry. Designed for business development, licensing, and corporate strategy professionals, the report delivers detailed insight into how companies structure asset purchase deals and negotiate the financial terms behind these transactions.

Fully revised and updated, the report analyzes asset purchase agreements announced since 2019, providing a detailed view of how pharmaceutical and biotechnology companies acquire business assets, product assets, royalty interests, and technology assets through strategic transactions.

Each deal record includes financial terms where available and links to detailed online deal records and contract documents filed with regulators when publicly disclosed. This combination of deal data, financial benchmarking, and contract access enables users to evaluate comparable transactions and structure more effective asset acquisition strategies.

Key Benefits

Save Significant Research Time

Access a consolidated database of asset purchase deals rather than searching multiple press releases, databases, and regulatory filings.

Benchmark Asset Purchase Deal Structures

Understand how pharmaceutical and biotechnology companies structure asset acquisition agreements across business units, products, technologies, and royalty streams.

Analyze Financial Terms with Confidence

Review disclosed financial information-including headline deal values, upfront payments, milestones, and royalty arrangements-to benchmark transaction values and structures.

Access Real Contract Documents

Where available, explore SEC-filed asset purchase agreements, providing deeper insight into the contractual provisions behind real-world deals.

Identify the Most Active Asset Acquisition Dealmakers

Discover which companies are most active in asset acquisitions and analyze their strategic transaction activity.

Track Industry Trends

Analyze asset purchase dealmaking trends since 2019 across companies, therapeutic areas, and technology types.

What's Included in the Report

Analysis of asset purchase dealmaking trends since 2019

Overview of asset acquisition deal structures and transaction models

Review of the leading asset purchase deals by headline value

Profiles of the top 25 most active asset purchase dealmakers

Detailed analysis of deals organized by company, therapeutic area, technology type, and industry sector

A comprehensive deal directory covering asset purchase transactions announced since 2019

Links to online deal records and contract documents where available

Due Diligence Insights from Real Agreements

By reviewing actual asset purchase contracts, the report enables users to evaluate key transaction provisions such as:

Asset ownership and transfer rights
Financial payment structures and transaction values
Intellectual property rights and technology transfer provisions
Commercialization and development obligations
Royalty structures and ongoing financial participation
Contract duration and termination provisions
Access to real agreements provides insight into the detailed terms negotiated between companies-information rarely disclosed in press releases or traditional deal databases.
Why This Report Matters
Asset purchase transactions are an important strategic tool in the pharmaceutical and biotechnology industries, enabling companies to acquire technologies, products, and royalty streams to strengthen their pipelines and portfolios.
By combining comprehensive deal data, financial benchmarking, and access to real contract documents, this report provides the intelligence needed to evaluate acquisition opportunities, structure stronger asset purchase agreements, and negotiate more effectively.

Product Code: CP2054

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in asset purchase dealmaking

2.1. Introduction
2.2. Types of assets purchased
2.3. Trends in asset purchase deals since 2019
- 2.3.1. Asset purchase dealmaking by year
- 2.3.2. Asset purchase dealmaking by phase of development
- 2.3.3. Asset purchase dealmaking by industry sector
- 2.3.4. Asset purchase dealmaking by therapy area
- 2.3.5. Asset purchase dealmaking by technology type
- 2.3.6. Asset purchase dealmaking by most active company
2.4. Reasons for entering into asset purchase partnering deals
- 2.4.1. Business assets
- 2.4.2. Product assets
- 2.4.3. Royalty assets
- 2.4.4. Technology assets
2.5. The future of asset purchase deals

Chapter 3 - Overview of asset purchase deal structure

3.1. Introduction
3.2. Asset purchase agreement structure

Chapter 4 - Leading asset purchase deals

4.1. Introduction
4.2. Top asset purchase deals by value

Chapter 5 - Top 25 most active asset purchase dealmakers

5.1. Introduction
5.2. Top 25 most active asset purchase dealmakers

Chapter 6 - Asset purchase deals including contracts directory

6.1. Introduction
6.2. Asset purchase deals with contracts
Deal directory
Deal directory - Asset purchase dealmaking by companies A-Z
Deal directory - Asset purchase dealmaking by therapy area
Deal directory - Asset purchase dealmaking by technology type
About Biopharma Research Ltd
Current Partnering
Current Agreements
Recent report titles from Current Partnering

TABLE OF FIGURES

Figure 1: Definition of assets purchased
Figure 2: Trends in asset purchase deal announcements
Figure 3: Asset purchase deals signed at each phase of development
Figure 4: Asset purchase deals by industry sector
Figure 5: Asset purchase deals by therapy area
Figure 6: Asset purchase deals by technology type
Figure 7: Top 25 most active asset purchase dealmakers
Figure 8: Top asset purchase deals by value
Figure 9: Most active asset purchase dealmakers